Opportunity Information: Apply for HRSA 12 038
Apply for HRSA 12 038
- The Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Genetic Services Grants to Support Comprehensive Medical Care for Thalassemia (CMCT)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.110 Maternal and Child Health Federal Consolidated Programs.
- This funding opportunity was created on Oct 14, 2011 and posted on Oct 14, 2011.
- Applicants must submit their applications by Dec 16, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $516,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification).
- As cited in 42 CFR Part 51 a.3(a), any public or private entity, including an Indian Tribe or Tribal organization (as those terms are defined in 25 U.S.C. 450b) is eligible to apply for this federal funding opportunity. Faith based and community based organizations are eligible to apply for these grants. Applicants must demonstrate no less than five (5) years of cumulative experience in providing a system of comprehensive care and medical management for individuals and families at risk for or affected by Thalassemia.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Genetic Services - Grants to Support Comprehensive Medical Care for Thalassemia (CMCT) opportunity (HRSA-12-038) is a discretionary grant program from the Health Resources and Services Administration (HRSA) under CFDA 93.110 (Maternal and Child Health Federal Consolidated Programs). Its core goal is to fund up to three demonstration projects that can operate as model centers for comprehensive, coordinated medical care and long-term management for individuals and families who are at risk for or affected by thalassemia. The emphasis is on building and demonstrating an integrated system of care rather than supporting isolated clinical services, with the expectation that funded projects will show how multiple clinical and support components can work together in a consistent, replicable way.
Funded projects are expected to deliver a complex network of services spanning the full continuum of thalassemia care. This includes screening and diagnosis, as well as counseling and education so that patients and families understand the condition, inheritance patterns, treatment expectations, and self-management needs. The model also requires psychosocial services, reflecting the reality that thalassemia management is lifelong and can place significant emotional, social, and practical burdens on patients and caregivers. On the medical side, the program highlights the need for specialized care that typically includes regular red blood cell transfusions, along with systematic monitoring for transfusion-related complications. A major clinical focus is prevention, detection, and treatment of iron overload, a common and serious consequence of repeated transfusions, as well as broader medical complications associated with long-term transfusion therapy. In practice, this implies strong clinical protocols, reliable follow-up systems, and access to specialists and diagnostics necessary for ongoing surveillance and timely intervention.
Collaboration is a central requirement of the CMCT approach. Funded centers are expected to work closely with consumer and patient advocacy organizations, specifically naming the Cooley's Anemia Foundation as an example, and to coordinate with other relevant entities such as hospitals, agencies, and community organizations. Beyond local partnerships, awardees are also expected to collaborate with other Maternal and Child Health Bureau (MCHB)-funded hemoglobinopathy initiatives, including the Sickle Cell Disease Newborn Screening Programs (SCDNBSP), Sickle Cell Disease Treatment Demonstration Programs (SCDTDP), and the National Coordinating Center(s) associated with those programs. This cross-program alignment signals that HRSA is looking for coordination across related blood disorder systems, shared learning, and consistent approaches to care delivery where appropriate, rather than siloed disease-specific efforts.
In terms of funding and timing, HRSA anticipated making three awards with an estimated total program funding level of $516,000. The funding instrument is a grant, and there is no cost sharing or matching requirement listed, which can lower the barrier to participation for organizations that have strong clinical capacity but limited ability to provide non-federal matching funds. The opportunity was posted on October 14, 2011, with an original and current closing date of December 16, 2011, and it was archived on February 14, 2012.
Eligibility is broad in organizational type but narrow in demonstrated experience. Under 42 CFR Part 51a.3(a), any public or private entity may apply, including Indian Tribes or Tribal organizations (as defined in 25 U.S.C. 450b). Faith-based and community-based organizations are explicitly eligible as well, and the listing also includes Native American tribal organizations other than federally recognized tribal governments. However, applicants must be able to demonstrate at least five years of cumulative experience providing a system of comprehensive care and medical management for people and families affected by or at risk for thalassemia. This experience requirement strongly indicates the program is aimed at established thalassemia care providers or networks that can credibly implement and demonstrate a mature, multidisciplinary model rather than newly formed programs.
For applicants or interested parties who need assistance accessing the full announcement, HRSA provided support through the HRSA Call Center (CallCenter@HRSA.GOV) and phone contact options (877-464-4772 and 301-998-7373). The archived announcement also referenced an external HRSA grants link for full details.
Frequently Asked Questions (FAQs)
1) What is the name of this grant opportunity?
The opportunity is titled Genetic Services - Grants to Support Comprehensive Medical Care for Thalassemia (CMCT), opportunity number HRSA-12-038.
2) Which federal agency is offering the CMCT grant?
The program is offered by the Health Resources and Services Administration (HRSA).
3) What CFDA program is this grant associated with?
This opportunity is under CFDA 93.110, described as Maternal and Child Health Federal Consolidated Programs.
4) What is the main purpose or goal of the CMCT grant?
The core goal is to fund up to three demonstration projects that can operate as model centers for comprehensive, coordinated medical care and long-term management for individuals and families who are at risk for or affected by thalassemia.
5) How many awards did HRSA anticipate making under this opportunity?
HRSA anticipated making three awards.
6) What was the estimated total program funding level?
The estimated total program funding level was $516,000.
7) What type of funding instrument is used?
The funding instrument is a grant.
8) Is cost sharing or matching required?
No. The opportunity indicates there is no cost sharing or matching requirement listed.
9) What does HRSA mean by a “demonstration project†or “model center†in this program?
Based on the description, HRSA is looking for projects that build and demonstrate an integrated system of care for thalassemia. The emphasis is on showing how multiple clinical and support components work together in a consistent and replicable way, rather than funding isolated or standalone clinical services.
10) Is the program intended to fund isolated clinical services?
No. The opportunity emphasizes integrated systems of care rather than supporting isolated clinical services.
11) Who should be served by funded CMCT projects?
Funded projects are intended to serve individuals and families who are at risk for or affected by thalassemia.
12) What types of services are expected as part of a comprehensive thalassemia care model?
The funded model is described as a network of services across the continuum of thalassemia care, including:
- Screening and diagnosis
- Counseling and education so patients/families understand the condition, inheritance patterns, treatment expectations, and self-management needs
- Psychosocial services to address lifelong emotional, social, and practical burdens
- Specialized medical care that typically includes regular red blood cell transfusions
- Systematic monitoring for transfusion-related complications
- Prevention, detection, and treatment of iron overload
- Monitoring and management of broader medical complications associated with long-term transfusion therapy
13) What medical management topics does HRSA highlight as especially important?
The program highlights regular red blood cell transfusions (as typical specialized care), strong monitoring for transfusion-related complications, and a major focus on prevention, detection, and treatment of iron overload, which is described as a common and serious consequence of repeated transfusions.
14) Why are psychosocial services included in the expected model of care?
The opportunity notes that thalassemia management is lifelong and can create significant emotional, social, and practical burdens for patients and caregivers. Psychosocial services are included to address those needs as part of comprehensive care.
15) What does the opportunity imply about follow-up and clinical protocols?
The description implies the need for strong clinical protocols, reliable follow-up systems, and access to the specialists and diagnostics required for ongoing surveillance and timely intervention, especially related to transfusion therapy and iron overload.
16) Are partnerships and collaboration required?
Yes. Collaboration is described as a central requirement of the CMCT approach, including coordination with advocacy organizations and alignment with other HRSA/MCHB hemoglobinopathy initiatives.
17) Which consumer or patient advocacy organization is specifically named?
The opportunity specifically names the Cooley's Anemia Foundation as an example of a consumer and patient advocacy organization for collaboration.
18) What other types of organizations are funded centers expected to coordinate with?
Funded centers are expected to coordinate with relevant entities such as hospitals, agencies, and community organizations.
19) What other HRSA/MCHB hemoglobinopathy initiatives are awardees expected to collaborate with?
Awardees are expected to collaborate with other MCHB-funded initiatives, including:
- Sickle Cell Disease Newborn Screening Programs (SCDNBSP)
- Sickle Cell Disease Treatment Demonstration Programs (SCDTDP)
- The National Coordinating Center(s) associated with those programs
20) What is HRSA signaling by requiring cross-program collaboration?
Based on the description, HRSA is signaling an expectation for coordination across related blood disorder systems, shared learning, and consistent approaches to care delivery where appropriate, rather than siloed, disease-specific efforts.
21) Who is eligible to apply (organizational types)?
Eligibility is broad by organizational type. Under 42 CFR Part 51a.3(a), any public or private entity may apply, including:
- Indian Tribes or Tribal organizations (as defined in 25 U.S.C. 450b)
- Faith-based organizations
- Community-based organizations
- Native American tribal organizations other than federally recognized tribal governments
22) Is eligibility based only on organizational type?
No. While organizational eligibility is broad, applicants must also meet a specific experience requirement related to thalassemia comprehensive care.
23) What experience must applicants demonstrate?
Applicants must demonstrate at least five years of cumulative experience providing a system of comprehensive care and medical management for people and families affected by or at risk for thalassemia.
24) What does the five-year experience requirement suggest about the type of applicants HRSA wants?
The description indicates the program is aimed at established thalassemia care providers or networks that can credibly implement and demonstrate a mature, multidisciplinary model, rather than newly formed programs.
25) When was the opportunity posted?
The opportunity was posted on October 14, 2011.
26) What was the application closing date?
The original and current closing date listed is December 16, 2011.
27) What does it mean that the opportunity is archived?
The announcement is described as archived, with an archive date of February 14, 2012.
28) Where can someone get help accessing the full announcement details?
HRSA provided assistance through the HRSA Call Center using:
- Email: CallCenter@HRSA.GOV
- Phone: 877-464-4772
- Phone: 301-998-7373
29) Was there a link mentioned for full details?
Yes. The archived announcement referenced an external HRSA grants link for full details.
30) What is the central theme of the CMCT care approach described?
The central theme is building a comprehensive, coordinated, integrated system of care for thalassemia that covers clinical treatment, monitoring, education, counseling, psychosocial support, and collaboration with advocacy and related HRSA initiatives.
Browse more opportunities from the same category: Health
Next opportunity: Children Youth and Families At Risk Sustainable Community Project
Previous opportunity: Secondary Education, Two Year Postsecondary Education, and Agriculture in the K 12 Classroom Challenge Grants Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 12 038
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 12 038) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition Framework Programs for Global Health Innovation (D43) Apply for PAR 12 003 Funding Number: PAR 12 003 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| EMSC State Partnership Regionalization of Care (SPROC) Apply for HRSA 12 126 Funding Number: HRSA 12 126 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Affordable Care Act Family to Family Health Information Centers Apply for HRSA 12 045 Funding Number: HRSA 12 045 Agency: Health Resources and Services Administration Category: Health Funding Amount: $95,700 |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) Apply for PAR 12 004 Funding Number: PAR 12 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Imaging of the Lung Phase 1 (R01) Apply for RFA HL 12 036 Funding Number: RFA HL 12 036 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Improving Access to Hearing Health Care (SBIR) R43/R44 Apply for RFA DC 12 004 Funding Number: RFA DC 12 004 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Improving Access to Hearing Health Care (STTR) R41/R42 Apply for RFA DC 12 005 Funding Number: RFA DC 12 005 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Service Area Competition Additional Area (SAC AA) (New York, NY) Apply for HRSA 12 167 Funding Number: HRSA 12 167 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Community Nutrition and Health Care Project Apply for USAID GUATEMALA 520 11 000004 Funding Number: USAID GUATEMALA 520 11 000004 Agency: Guatemala USAID Guatemala City Category: Health Funding Amount: $32,000,000 |
| Cardiovascular Research Network (CVRN) Limited Competition (U54) Apply for RFA HL 13 004 Funding Number: RFA HL 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Pilot Studies of Novel Mechanism of Action Compounds for Treating Psychiatric Disorders (U01) Apply for PAR 12 007 Funding Number: PAR 12 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Revision(s) to the Dominantly Inherited Alzheimer Network (U19) Apply for PAR 12 008 Funding Number: PAR 12 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implications of the Economic Downturn for Health, Wealth, and Work at Older Ages (R01) Apply for PA 12 009 Funding Number: PA 12 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nationwide Program for National and State Background Checks for Direct Patient Access Employees of Long Term Care Facilities and Providers Apply for CMS 1A1 12 002 Funding Number: CMS 1A1 12 002 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $3,000,000 |
| Support to the Zimbabwe MOH and Child Welfare s Program for PMTCT of HIV. Apply for 674 12 1003 EXPRESSION OF INTEREST Funding Number: 674 12 1003 EXPRESSION OF INTEREST Agency: South Africa USAID Pretoria Category: Health Funding Amount: $60,000,000 |
| HIV Incidence Assays with Improved Specificity (R01) Apply for PA 12 012 Funding Number: PA 12 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Early Independence Awards (DP5) Apply for RFA RM 11 007 Funding Number: RFA RM 11 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Data Coordinating Center for Autism and Other Developmental Disabilities Research and Epidemiologic Studies (U10) Apply for RFA DD 12 001 Funding Number: RFA DD 12 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Area Health Education Centers Apply for HRSA 12 013 Funding Number: HRSA 12 013 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Health Care Innovation Challenge Apply for CMS 1C1 12 001 Funding Number: CMS 1C1 12 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $30,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 12 038", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.